10/509,052

~~10/513699~~

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAEAL1624

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2	JAN 08	CHEMLIST enhanced with New Zealand Inventory of Chemicals
NEWS 3	JAN 16	CA/CAplus Company Name Thesaurus enhanced and reloaded
NEWS 4	JAN 16	IPC version 2007.01 thesaurus available on STN
NEWS 5	JAN 16	WPIDS/WPINDEX/WPIX enhanced with IPC 8 reclassification data
NEWS 6	JAN 22	CA/CAplus updated with revised CAS roles
NEWS 7	JAN 22	CA/CAplus enhanced with patent applications from India
NEWS 8	JAN 29	PHAR reloaded with new search and display fields
NEWS 9	JAN 29	CAS Registry Number crossover limit increased to 300,000 in multiple databases
NEWS 10	FEB 15	PATDPASPC enhanced with Drug Approval numbers
NEWS 11	FEB 15	RUSSIAPAT enhanced with pre-1994 records
NEWS 12	FEB 23	KOREAPAT enhanced with IPC 8 features and functionality
NEWS 13	FEB 26	MEDLINE reloaded with enhancements
NEWS 14	FEB 26	EMBASE enhanced with Clinical Trial Number field
NEWS 15	FEB 26	TOXCENTER enhanced with reloaded MEDLINE
NEWS 16	FEB 26	IFICDB/IFIPAT/IFIUDB reloaded with enhancements
NEWS 17	FEB 26	CAS Registry Number crossover limit increased from 10,000 to 300,000 in multiple databases
NEWS 18	MAR 15	WPIDS/WPIX enhanced with new FRAGHITSTR display format
NEWS 19	MAR 16	CASREACT coverage extended
NEWS 20	MAR 20	MARPAT now updated daily
NEWS 21	MAR 22	LWPI reloaded
NEWS 22	MAR 30	RDISCLOSURE reloaded with enhancements
NEWS 23	MAR 30	INPADOCDB will replace INPADOC on STN
NEWS 24	APR 02	JICST-EPLUS removed from database clusters and STN

NEWS EXPRESS NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

<12/04/2007> Erich Leese

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

*IFIREF - The IFI Uniterm and U.S. Class Reference File

* The files listed above are temporarily unavailable.

FILE 'HOME' ENTERED AT 14:54:39 ON 23 APR 2007

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 14:54:48 ON 23 APR 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 20 APR 2007 HIGHEST RN 931582-00-2
DICTIONARY FILE UPDATES: 20 APR 2007 HIGHEST RN 931582-00-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\10509052new.str

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 C,H,O,X

G2 C,H,O,S,N

G3 C,O,N

Structure attributes must be viewed using STN Express query preparation.

```
=> s l1
SAMPLE SEARCH INITIATED 14:55:25 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -        3 TO ITERATE

100.0% PROCESSED         3 ITERATIONS                                 1 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:            3 TO      163
PROJECTED ANSWERS:               1 TO       80

L2             1 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 14:55:32 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -       63 TO ITERATE

100.0% PROCESSED        63 ITERATIONS                                29 ANSWERS
SEARCH TIME: 00.00.01

L3            29 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   172.10     172.31

FILE 'CAPLUS' ENTERED AT 14:55:40 ON 23 APR 2007
```

FILE COVERS 1907 - 23 Apr 2007 VOL 146 ISS 18
FILE LAST UPDATED: 22 Apr 2007 (20070422/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l3 full
L4 2 L3

=> d ibib abs hitstr

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:777520 CAPLUS
DOCUMENT NUMBER: 139:292269
TITLE: Preparation of 4-(diarylmethyl)-1-piperazine derivatives as antihistaminics
INVENTOR(S): Midha, Ajay Sohanlal; Chokshi, Hemant Ashvinbhai; Chitturi, Trinadha Rao; Thennati, Rajamannar
PATENT ASSIGNEE(S): Sun Pharmaceutical Industries Limited, India
SOURCE: PCT Int. Appl., 37 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003079970	A2	20031002	WO 2003-IN89	20030327
WO 2003079970	A3	20031106		
WO 2003079970	A8	20050324		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

IN 2002MU00302	A	20050304	IN 2002-MU302	20020327

CA 2480367	A1	20031002	CA 2003-2480367		20030327
AU 2003231921	A1	20031008	AU 2003-231921		20030327
EP 1487810	A2	20041222	EP 2003-744972		20030327
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
BR 2003008913	A	20050104	BR 2003-8913		20030327
US 2005107393	A1	20050519	US 2003-509052		20030327
CN 1649856	A	20050803	CN 2003-809564		20030327
JP 2005527533	T	20050915	JP 2003-577803		20030327
NZ 535476	A	20060331	NZ 2003-535476		20030327
ZA 2004007731	A	20060222	ZA 2004-7731		20040923
PRIORITY APPLN. INFO.:			IN 2002-MU302	A	20020327
			WO 2003-IN89	W	20030327

OTHER SOURCE(S): MARPAT 139:292269

GI



I

AB The title compds. of formula (I) [wherein X, Y, X1, Y1 = H, halogen, (un)substituted linear, branched, or cyclic alkyl, aryl, alkyloxy, haloalkyl; R1, R2, R3, R4 = H, (un)substituted linear, branched, or cyclic alkyl, aryl, heteroaryl groups or aralkyl groups, heterocycles containing one or more of hetero atoms selected from N, S, and O, (un)substituted C2-6 alkenyl or alkynyl; wherein R1 and R2 on the piperazinyl moiety are either syn or anti to each other and optionally R3 and R4 together with the carbons to which they are attached form a monocyclic saturated aryl or substituted aryl or heteroaryl or substituted heteroaryl ring containing one or more hetero atoms selected from N, S and O with a ring size ranging from 3 to 6 with a proviso that when R3 and R4 together do not form part of a ring they may exist in either E or Z configuration; R5 = (CH2)nOCH2CO-Z (wherein n = 1-6; Z = OH, OR, NRR', N(OR)R', N(R)N(R)R', etc. and wherein R, R' = H, (un)substituted linear, branched or cyclicalkyl, aryl, heteroaryl, aralkyl, heterocycles containing one or more of hetero atoms selected from N, S, and O, (un)substituted C2-6 alkenyl or alkynyl); m = 1 to 6] and pharmaceutically acceptable salts thereof are prepared These compds. are useful for treating histamine-mediated diseases. Thus, to a stirred solution of 4-[4-[bis(4-fluorophenyl)methyl]piperazin-1-yl]-(Z)-but-2-en-1-ol > (97.0 g, 0.271 mol) and potassium tert-butoxide (54.7 g, 0.487 mol) in anhydrous tert-butanol (776 mL), preheated at 60-65° for 1 h under nitrogen atmospheric, was added dry sodium chloroacetate (63 g, 0.541 mol) and then refluxed for further 5 h, and concentrated under reduced pressure at below 60° until tert-butanol was completely removed to give, after workup and silica gel chromatog.,

[4-[4-[bis(4-fluorophenyl)methyl]piperazin-1-yl]-(Z)-but-2-enyloxy]acetic acid (II). II.2HCl and [4-(4-Benzhydrylpiperazin-1-yl)-(Z)-but-2-enyloxy]acetic acid dihydrochloride inhibited the histamine-stimulated contraction of isolated guinea pig ileum with IC50 of 2.17X10-7±4.23X10-7 and 1.30X10-7±4.17X10-7 mol, resp.

IT 607736-71-0P 607736-72-1P 607736-73-2P
607736-74-3P 607736-75-4P 607736-76-5P
607736-77-6P 607736-78-7P 607736-79-8P
607736-80-1P 607736-81-2P 607736-84-5P
607736-85-6P 607736-86-7P 607736-87-8P,
[[4-[4-[Bis(4-fluorophenyl)methyl]piperazin-1-yl]-(Z)-but-2-enyl]oxy]acetic acid 607736-88-9P, [[4-[4-[(4-Chlorophenyl)phenylmethyl]piperazin-1-yl]-(Z)-but-2-enyl]oxy]acetic acid 607736-89-0P, [[4-(4-Benzhydrylpiperazin-1-yl)-(Z)-but-2-enyl]oxy]acetic acid 607736-90-3P, [[4-[4-[Bis(2,4-difluorophenyl)methyl]piperazin-1-yl]-(Z)-but-2-enyl]oxy]acetic acid 607736-91-4P, [[4-[4-[Bis(4-chlorophenyl)methyl]piperazin-1-yl]-(Z)-but-2-enyl]oxy]acetic acid 607736-92-5P, [[4-[4-[Bis(4-fluorophenyl)methyl]piperazin-1-yl]-(Z)-but-2-enyl]oxy]acetic acid methyl ester 607736-93-6P, [[4-[4-[Bis(4-fluorophenyl)methyl]piperazin-1-yl]-(Z)-but-2-enyl]oxy]acetic acid ethyl ester 607736-94-7P, [[4-[4-[Bis(4-fluorophenyl)methyl]piperazin-1-yl]-(Z)-but-2-enyl]oxy]acetic acid isopropyl ester 607736-95-8P, [[4-[4-[(4-Chlorophenyl)phenylmethyl]piperazin-1-yl]-(Z)-but-2-enyl]oxy]acetic acid isopropyl ester 607736-96-9P, [[4-[4-[(4-Chlorophenyl)phenylmethyl]piperazin-1-yl]-(Z)-but-2-enyl]oxy]acetic acid methyl ester 607736-97-0P, [[4-[4-[(4-Chlorophenyl)phenylmethyl]piperazin-1-yl]-(Z)-but-2-enyl]oxy]acetic acid ethyl ester 607737-00-8P, [[4-[4-[Bis(4-fluorophenyl)methyl]piperazin-1-yl]-(E)-but-2-enyl]oxy]acetic acid 607737-01-9P, [[4-[4-[(4-Chlorophenyl)phenylmethyl]piperazin-1-yl]-(E)-but-2-enyl]oxy]acetic acid
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 4-(diarylmethyl)-1-piperazine derivs. as antihistaminics for treatment of histamine-stimulated diseases)

RN 607736-71-0 CAPLUS

CN Acetic acid, [[(2Z)-4-[4-[bis(4-fluorophenyl)methyl]-1-piperazinyl]-2-butenyl]oxy]-, dihydrochloride (9CI) (CA INDEX NAME)

Double bond geometry as shown.



●2 HCl

RN 607736-72-1 CAPLUS
CN Acetic acid, [[(2Z)-4-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]-2-butenyl]oxy]-, dihydrochloride (9CI) (CA INDEX NAME)

Double bond geometry as shown.



●2 HCl

RN 607736-73-2 CAPLUS
CN Acetic acid, [[(2Z)-4-[4-(diphenylmethyl)-1-piperazinyl]-2-butenyl]oxy]-, dihydrochloride (9CI) (CA INDEX NAME)

Double bond geometry as shown.



●2 HCl

RN 607736-74-3 CAPLUS
CN Acetic acid, [[(2Z)-4-[4-[bis(2,4-difluorophenyl)methyl]-1-piperazinyl]-2-butenyl]oxy]-, dihydrochloride (9CI) (CA INDEX NAME)

Double bond geometry as shown.



●2 HCl

RN 607736-75-4 CAPLUS
CN Acetic acid, [[(2Z)-4-[4-[bis(4-chlorophenyl)methyl]-1-piperazinyl]-2-butenyl]oxy]-, dihydrochloride (9CI) (CA INDEX NAME)

Double bond geometry as shown.



●2 HCl

RN 607736-76-5 CAPLUS
CN Acetic acid, [[(2Z)-4-[4-[bis(4-fluorophenyl)methyl]-1-piperazinyl]-2-butenyl]oxy]-, methyl ester, dihydrochloride (9CI) (CA INDEX NAME)

Double bond geometry as shown.



●2 HCl

RN 607736-77-6 CAPLUS
CN Acetic acid, [[(2Z)-4-[4-[bis(4-fluorophenyl)methyl]-1-piperazinyl]-2-butenyl]oxy]-, ethyl ester, dihydrochloride (9CI) (CA INDEX NAME)

Double bond geometry as shown.



●2 HCl

RN 607736-78-7 CAPLUS
CN Acetic acid, [[(2Z)-4-[4-[bis(4-fluorophenyl)methyl]-1-piperazinyl]-2-butenyl]oxy]-, 1-methylethyl ester, dihydrochloride (9CI) (CA INDEX NAME)

Double bond geometry as shown.



●2 HCl

RN 607736-79-8 CAPLUS
CN Acetic acid, [[(2Z)-4-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]-2-butenyl]oxy]-, 1-methylethyl ester, dihydrochloride (9CI) (CA INDEX NAME)

Double bond geometry as shown.



●2 HCl

RN 607736-80-1 CAPLUS
CN Acetic acid, [[(2Z)-4-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]-2-butenyl]oxy]-, methyl ester, dihydrochloride (9CI) (CA INDEX NAME)

Double bond geometry as shown.



●2 HCl

RN 607736-81-2 CAPLUS
CN Acetic acid, [[(2Z)-4-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]-2-

butenyl]oxy]-, ethyl ester, dihydrochloride (9CI) (CA INDEX NAME)

Double bond geometry as shown.



●2 HCl

RN 607736-84-5 CAPLUS
CN Acetic acid, [[(2E)-4-[4-[bis(4-fluorophenyl)methyl]-1-piperazinyl]-2-butenyl]oxy]-, dihydrochloride (9CI) (CA INDEX NAME)

Double bond geometry as shown.



●2 HCl

RN 607736-85-6 CAPLUS
CN Acetic acid, [[(2E)-4-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]-2-butenyl]oxy]-, dihydrochloride (9CI) (CA INDEX NAME)

Double bond geometry as shown.



●2 HCl

RN 607736-86-7 CAPLUS
CN Acetic acid, [[(2E)-4-[4-[(4-fluorophenyl)phenylmethyl]-1-piperazinyl]-2-butenyl]oxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 607736-87-8 CAPLUS
CN Acetic acid, [[(2Z)-4-[4-[bis(4-fluorophenyl)methyl]-1-piperazinyl]-2-butenyl]oxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 607736-88-9 CAPLUS
CN Acetic acid, [[(2Z)-4-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]-2-butenyl]oxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 607736-89-0 CAPLUS
CN Acetic acid, [[(2Z)-4-[4-(diphenylmethyl)-1-piperazinyl]-2-butenyl]oxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 607736-90-3 CAPLUS
CN Acetic acid, [[(2Z)-4-[4-[bis(2,4-difluorophenyl)methyl]-1-piperazinyl]-2-butenyl]oxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 607736-91-4 CAPLUS
CN Acetic acid, [[(2Z)-4-[4-[bis(4-chlorophenyl)methyl]-1-piperazinyl]-2-butenyl]oxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 607736-92-5 CAPLUS
CN Acetic acid, [[(2Z)-4-[4-[bis(4-fluorophenyl)methyl]-1-piperazinyl]-2-butenyl]oxy]-, methyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 607736-93-6 CAPLUS
CN Acetic acid, [[(2Z)-4-[4-[bis(4-fluorophenyl)methyl]-1-piperazinyl]-2-butenyl]oxy]-, ethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 607736-94-7 CAPLUS
CN Acetic acid, [[(2Z)-4-[4-[bis(4-fluorophenyl)methyl]-1-piperazinyl]-2-butenyl]oxy]-, 1-methylethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 607736-95-8 CAPLUS
CN Acetic acid, [[(2Z)-4-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]-2-

butenyl]oxy]-, 1-methylethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 607736-96-9 CAPLUS
CN Acetic acid, [[(2Z)-4-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]-2-butenyl]oxy]-, methyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 607736-97-0 CAPLUS
CN Acetic acid, [[(2Z)-4-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]-2-butenyl]oxy]-, ethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 607737-00-8 CAPLUS
CN Acetic acid, [[(2E)-4-[4-[bis(4-fluorophenyl)methyl]-1-piperazinyl]-2-butenyl]oxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 607737-01-9 CAPLUS
CN Acetic acid, [[(2E)-4-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]-2-butenyl]oxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



=> d ibib abs hitstr 2

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1995:933969 CAPLUS
DOCUMENT NUMBER: 124:8843
TITLE: Preparation of piperazine derivatives as allergy inhibitors
INVENTOR(S): Kuki, Masakatsu; Muneda, Yasuji; Imahori, Hidekazu; Oota, Yoichiro; Kawanishi, Kenji; Bonshihara, Yasuko; Iwakura, Bungetsu; Akimoto, Yoshinobu; Sakamoto, Hirohiko; Et, Al.
PATENT ASSIGNEE(S): Nippon Shoji Kk, Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 29 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 07138230	A	19950530	JP 1993-283111	19931112
JP 3352184	B2	20021203		
PRIORITY APPLN. INFO.:			JP 1993-283111	19931112

OTHER SOURCE(S): MARPAT 124:8843
GI



I



II



III

AB The title compds. I [R1 = alkyl, etc. R2 = OH, etc.; A = Ph, etc.; Y = alkylene having one or more double or triple bonds; n = 0 - 3] are prepared The title compound II.2HCl at 10 mg/Kg orally gave 90.5% inhibition of passive cutaneous anaphylaxis reaction in rats, vs. 56.9 - 69.9% inhibition by ketotifen at 10 mg/Kg orally. The title compound III.2HCl at 10 mg/Kg orally gave 76.6% inhibition of passive cutaneous anaphylaxis reaction in rats.

IT 170627-15-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of piperazine derivs. as allergy inhibitors)

RN 170627-15-3 CAPLUS

CN 2-Butenoic acid, 4-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]-, 2-ethoxy-2-oxoethyl ester, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl